Product details & mandatory information
HYLO DUAL INTENSE® in detail
Active ingredients:
- 20 mg ectoine
- 2 mg hyaluronic acid, sodium salt
Excipients:
- Water for injection
- boric acid
- Sodium tetraborate
HYLO DUAL INTENSE® eye drops offer an effective solution for chronically dry and irritated eyes with inflammatory symptoms. The combination of 0.2% hyaluronic acid and 2.0% ectoine stabilises the tear film and protects the surface of the eye from drying out and irritation in the long term. The drops support the body's own barrier function against inflammatory irritation and are free from preservatives and phosphates.
Application:
- Remove the protective cap before use.
- Hold the bottle with the dropper tip pointing downwards, place your thumb on the shoulder of the bottle and your other fingers on the base of the bottle.
- Tilt your head back slightly and pull the lower eyelid down slightly.
- Apply firm pressure to the bottom of the bottle and drip a drop into the conjunctival sac.
- Close the eye slowly to distribute the liquid. Close the dropper tip immediately after use.
Special features:
- Patented COMOD® system: At least 300 drops per bottle, long shelf life of 6 months.
- Versatile protection: Relieves irritation caused by the environment and typical symptoms of dry eyes such as itching and burning.
Suitable for:
- People with chronically dry eyes.
- Users who require intensive and long-lasting moisturisation.
- People who suffer from inflammatory eye symptoms.
Advantages
- Solution for dry eyes with inflammatory symptoms
- Intensive treatment with 0.2% hyaluronic acid and 2.0% ectoine
- Sustained moisturisation and long-lasting relief from inflammatory symptoms
Important notes
For risks and side effects, read the package leaflet and ask your doctor or pharmacist.
The seller reserves the right to carry out a pharmaceutical check by our pharmacists on the quantity of the medicine ordered. This may result in reductions in your order for this product. The invoice amount will then be adjusted automatically.
The reason for this is our pharmaceutical duty of care.
